Lydia
Analyst
Goldman Sachs
Equibles does not estimate personal net worth.
About Lydia
Lydia is recorded as Analyst at Goldman Sachs. Lydia has spoken on 3 earnings calls and 5 other investor events across 4 companies, most recently for Ultragenyx Pharmaceutical Inc. on September 17, 2026. Those appearances were for Agios Pharmaceuticals, Inc. (AGIO), Ultragenyx Pharmaceutical Inc. (RARE), Incyte Corp (INCY) and Taysha Gene Therapies, Inc. (TSHA). The companies whose calls Lydia spoke on are classified in the Healthcare sector.
Lydia on recent calls
“Could you just speak to the overlap with the prescriber base with your existing commercial franchise and also the sales force that has been deployed for GenVycos?”
“Could you just speak broadly to the current breakout between transfusion and non-transfusion dependent patients and when you anticipate the non-transfusion population to make up a majority of patients on treatment.”
“Maybe just another for the two physicians on the call. Could you just speak to what percentage of your sickle cell patients receive transfusions regularly? Looks like it was around 25% of patients in the Rise Up study.”
“Maybe just another for the two physicians on the call. Could you just speak to what percentage of your sickle cell patients receive transfusions regularly? Looks like it was around 25% of patients in the Rise Up study.”
“Could you just speak to strategically the timing of the deal and then also any risks related to the VGA039's mechanism, particularly around thrombo-amelic events?”
Affiliation history
-
Goldman Sachs
Analyst
Transcript header (unverified)
Current
Company network
Incyte Corp
INCY
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-06-08
View calls and events